New drug versus standard chemo for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new drug called SYS6010 to a standard chemotherapy drug (docetaxel) for people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the new drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced (stage IIIB/IV) non-squamous non-small cell lung cancer (NSCLC) that is EGFR wild-type (no specific EGFR mutation).
- Your cancer must have progressed after receiving certain prior treatments (like platinum-based chemotherapy and/or immunotherapy, or targeted therapy if you have a driver gene mutation).
- You must have at least one measurable tumor on a CT or MRI scan.
- You must be in good physical condition (ECOG performance status 0-1).
- Your organ and bone marrow function must be within acceptable limits (specific blood counts and liver/kidney function tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new drug, SYS6090, combined with other treatments for advanced non-small cell or small cell lung cancer that has spread and can't be removed by surgery. It aims to see if this combination can help shrink or control the cancer, and how safe it is for patients.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.